Business Context and Reporting Period
This Form 8-K Current Report, filed on February 28, 2024, covers events occurring on February 23, 2024, and February 27, 2024, for vTv Therapeutics Inc. (VTVT). The filing details a material definitive agreement involving a private placement of equity securities, significant changes to the Board of Directors, and executive compensation adjustments.
Key Financial Metrics and Capital Structure
- Capital Raised: The Company received aggregate gross proceeds of approximately $51.0 million from the Private Placement.
- Securities Issued:
- 464,377 shares of Class A Common Stock at $11.81 per share.
- Pre-Funded Warrants to purchase up to 3,853,997 shares of Common Stock at $11.80 per warrant.
- Pricing Basis: Prices were based on a 45-day volume-weighted average price.
- Future Financing Rights: Purchasers have the right to purchase up to an additional $30.0 million of Common Stock 18 months following the closing.
- Revenue/Profit/Cash Flow: The filing text does not provide specific revenue, profit, cash flow, or margin data for the reporting period.
Material Changes and Corporate Actions
Board of Directors Changes
Significant turnover occurred on the Board of Directors in connection with the Private Placement:
- Resignations: Jonathan Isaacsohn and Hersh Kozlov resigned effective upon closing. John A. Fry and Howard L. Weiner agreed to resign effective upon the filing of the 2023 10-K. Keith Harris agreed to resign effective after the 2023 10-K filing and the appointment of a new director.
- Appointments: Raymond Cheong and Srinivas Akkaraju were elected as directors, contingent on the closing of the Private Placement. Both are affiliated with the lead Purchasers.
Executive Compensation Adjustments
Effective January 1, 2024, the Board approved changes for CEO Paul Sekhri:
- Base salary increased from $480,000 to $650,000.
- One-time bonus of $471,042.
- Target annual cash bonus percentage reduced from 75% to 60% of base salary.
- Grant of stock options to purchase 89,212 shares at $11.81 per share.
CFO Steven Tuch received stock options to purchase 62,159 shares at $11.81 per share.
Amendments to Existing Agreements
The Company amended agreements with G42 Investments, CinPax/CinRx, and M&F TTP Holdings. Key changes included:
- Removal of board designation rights for G42 and CinPax.
- Reduction of M&F's director nominee rights to two.
- Adjustments to piggyback registration rights priorities.
Guidance, Risks, and Covenants
- Commercialization Covenant: The Company must use commercially reasonable efforts to secure at least $30.0 million in gross proceeds from cash sales or royalty/licensing agreements related to drug candidates (excluding TTP 399).
- Beneficial Ownership Limitations: Pre-Funded Warrants are subject to beneficial ownership limits of 4.99% or 9.99%, extendable to 19.99% with 61 days' notice.
- Registration Rights: The Company agreed to register the resale of shares and warrant shares held by Purchasers, with the Company bearing registration expenses.
- Board Voting Procedures: New procedures require at least five directors to approve certain Company actions.
Investor Verification Checklist
- Verify the final closing date and net proceeds after deducting offering expenses.
- Confirm the exact composition of the new Board of Directors and the effective dates of all resignations.
- Review the specific terms of the "Commercialization Covenant" requiring $30.0 million in future proceeds.
- Assess the dilution impact of the 3,853,997 Pre-Funded Warrants and the potential $30.0 million future purchase right.
- Examine the amended agreements with G42, CinPax, and M&F for any remaining obligations or rights.